BXTAccelyon wins 2020 MedTech Breakthrough Award BXTAccelyon, the leading low dose rate brachytherapy partner to hospitals and clinics worldwide, and distribution partner for the PrecisionPoint™ freehand prostate biopsy system, is pleased to announce that MedTech Breakthrough has selected the PrecisionPoint Transperineal Access System™ as the ‘Best New Technology Solution - Biopsy’ in their 2020 Awards Program. The ‘Best New Technology Solution - Biopsy’ award, under the Medi
In the United Kingdom, Prostate Cancer is the most common cancer in men, with more than 47,500 diagnoses every year. With celebrities including Stephen Fry and Bill Turnbull announcing their own prostate cancer journey in recent years, the ‘Turnbull/Fry’ effect led to more men getting themselves checked for early warning signs and potentially saving themselves from adverse outcomes by getting an earlier diagnosis. Their stories resonate with that of Russell Stewart, a 69-year
David Robb was a 68-year-old retired secondary school teacher from Peebles, Scotland when he was diagnosed with prostate cancer last Summer. After two years of health checks following minor symptoms of LUTS, his PSA (prostate-specific antigen) level had risen from 3.8 from his first check in January 2017, to a score of 4.2 in July 2019. David refused to undertake a rectal exam and a blind biopsy, which are the basic processes in Scotland, until the doctors had performed a sca
“Before having a prostate cancer biopsy, I’d demand an MRI scan” These are the words of Dr Mark Porter, in his latest column on The Times. In addition to calling for all men with suspected prostate cancer to have access to an MRI scan as part of a better diagnostic pathway, Dr Porter also highlights the importance of the transperineal biopsy - as opposed to the traditional TRUS, or transrectal, biopsy, where the biopsy needle is inserted into the prostate through the rectum.